Mestanolone: Difference between revisions
CSV import |
CSV import |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|An androgen and anabolic steroid}} | |||
{{Drugbox | |||
| Verifiedfields = changed | |||
| verifiedrevid = 477318366 | |||
| image = [[File:Mestanolone_Structural_Formula_V2.svg|thumb|right|Structural formula of Mestanolone]] | |||
| IUPAC_name = (5α,17β)-17-Hydroxy-17-methylandrost-3-one | |||
| tradename = Androstalone | |||
| routes_of_administration = Oral | |||
| class = Androgen; Anabolic steroid | |||
| CAS_number = 521-11-9 | |||
}} | |||
'''Mestanolone''', also known by its brand name '''Androstalone''', is an [[androgen]] and [[anabolic steroid]] (AAS) that is used in the treatment of low testosterone levels in men. It is a synthetic derivative of [[dihydrotestosterone]] (DHT) and is known for its potent androgenic effects. | |||
Mestanolone | |||
== Pharmacology == | ==Pharmacology== | ||
Mestanolone is a | Mestanolone is an orally active androgen and anabolic steroid. It is a 17α-methylated derivative of DHT, which allows it to be taken orally. The compound binds to the [[androgen receptor]], leading to the expression of androgenic effects. Due to its structure, mestanolone is not aromatized into [[estrogens]], which means it does not cause estrogenic side effects such as gynecomastia. | ||
== | ===Mechanism of Action=== | ||
Mestanolone | Mestanolone acts by binding to the androgen receptor in target tissues. This binding initiates a cascade of events that result in the transcription of androgen-responsive genes. The effects include increased protein synthesis, muscle growth, and the development of male secondary sexual characteristics. | ||
== | ==Uses== | ||
Mestanolone is primarily used in the treatment of male hypogonadism, a condition characterized by low testosterone levels. It may also be used in certain cases of delayed puberty in boys and to treat breast cancer in women, although these uses are less common. | |||
== | ==Side Effects== | ||
The side effects of mestanolone are similar to those of other androgens and anabolic steroids. They include: | |||
* [[Acne]] | |||
* Increased body hair growth | |||
* Scalp hair loss | |||
* Increased aggression | |||
* Liver toxicity due to its 17α-methylation | |||
== | ==Chemistry== | ||
Mestanolone is a 17α-methylated derivative of dihydrotestosterone. Its chemical structure is characterized by the presence of a methyl group at the 17α position, which enhances its oral bioavailability. The compound is a white crystalline powder that is insoluble in water but soluble in alcohol and other organic solvents. | |||
==History== | |||
Mestanolone was first synthesized in the 1950s and has been used in clinical practice since then. It was developed as a means to provide the benefits of testosterone therapy with oral administration, avoiding the need for injections. | |||
==Related pages== | |||
* [[Androgen]] | |||
* [[Anabolic steroid]] | * [[Anabolic steroid]] | ||
* [[Dihydrotestosterone]] | * [[Dihydrotestosterone]] | ||
* [[ | * [[Testosterone]] | ||
[[Category: | [[Category:Androgens and anabolic steroids]] | ||
[[Category: | [[Category:Androstanes]] | ||
[[Category: | [[Category:Ketones]] | ||
[[Category:Secondary alcohols]] | |||
Latest revision as of 11:22, 23 March 2025
An androgen and anabolic steroid
| Mestanolone | |
|---|---|
[[File: | |
| INN | |
| Drug class | Androgen; Anabolic steroid |
| Routes of administration | Oral |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 521-11-9 |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Mestanolone, also known by its brand name Androstalone, is an androgen and anabolic steroid (AAS) that is used in the treatment of low testosterone levels in men. It is a synthetic derivative of dihydrotestosterone (DHT) and is known for its potent androgenic effects.
Pharmacology[edit]
Mestanolone is an orally active androgen and anabolic steroid. It is a 17α-methylated derivative of DHT, which allows it to be taken orally. The compound binds to the androgen receptor, leading to the expression of androgenic effects. Due to its structure, mestanolone is not aromatized into estrogens, which means it does not cause estrogenic side effects such as gynecomastia.
Mechanism of Action[edit]
Mestanolone acts by binding to the androgen receptor in target tissues. This binding initiates a cascade of events that result in the transcription of androgen-responsive genes. The effects include increased protein synthesis, muscle growth, and the development of male secondary sexual characteristics.
Uses[edit]
Mestanolone is primarily used in the treatment of male hypogonadism, a condition characterized by low testosterone levels. It may also be used in certain cases of delayed puberty in boys and to treat breast cancer in women, although these uses are less common.
Side Effects[edit]
The side effects of mestanolone are similar to those of other androgens and anabolic steroids. They include:
- Acne
- Increased body hair growth
- Scalp hair loss
- Increased aggression
- Liver toxicity due to its 17α-methylation
Chemistry[edit]
Mestanolone is a 17α-methylated derivative of dihydrotestosterone. Its chemical structure is characterized by the presence of a methyl group at the 17α position, which enhances its oral bioavailability. The compound is a white crystalline powder that is insoluble in water but soluble in alcohol and other organic solvents.
History[edit]
Mestanolone was first synthesized in the 1950s and has been used in clinical practice since then. It was developed as a means to provide the benefits of testosterone therapy with oral administration, avoiding the need for injections.
